SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.

Physiol Rep · 2019 · PMC6883099 · PMID 31782258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Pioglitazone also significantly or showed a trend toward significantly reducing these steatohepatitis parameters, and combined treatment comprising ipragliflozin and pioglitazone significantly and additively reduced these parameters.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.